These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2006-002372-18 Pilot Study of the Intravesical Administration of EOquin Immediately Following Transurethral Resection in Patients with Superficial Bladder Cancer. not-yet-due
Listed as ongoing, but also has a completion date and reported results 2008-005843-40 A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma 2014-10-27 bad-data
Not reported 2009-015404-26 A Multicenter, Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial of Single-Dose Intravesical EOquinĂ¢ as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing ... 2012-01-03 due-trials
Not reported 2011-003517-42 A Phase 3 International, Multicenter, Double-Blind, Placebo-Controlled, Randomized Trial Evaluating the Efficacy and Safety of Multiple Instillations of Intravesical Apaziquone vs. Placebo in Patients... 2013-02-21 due-trials
Listed as ongoing, but also has a completion date 2011-004916-51 A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (ibritumomab tiuxetan) versus Observation in Patients at Least 60 Years of Age with Newly Diagnosed Diffuse Large B-cell Lymp... 2014-10-30 bad-data
Listed as ongoing, but also has a completion date 2013-003094-10 Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim use for the Management of Neutropenia in Patients with Breast Cancer who are Candidates for Adjuvant and Neoadjuvant Chemotherapy w... 2015-02-06 bad-data
Ongoing 2016-003469-24 Randomized, OpEn-Label, Active-ContrOl Trial of SPI-2012 (Eflapegrastim) Versus Pegfilgrastim in the Management of Chemotherapy-Induced Neutropenia in Early-Stage BReast Cancer Patients Receiving Doce... not-yet-due
Ongoing 2018-001868-36 A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1) not-yet-due